Stockreport

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed N.V. - Ordinary Shares  (MYNZ) 
PDF Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including [Read more]